Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Depreciation & Amortization (CF) (2016 - 2025)

Heron Therapeutics' Depreciation & Amortization (CF) history spans 14 years, with the latest figure at $523000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 9.98% year-over-year to $523000.0; the TTM value through Dec 2025 reached $2.3 million, down 7.7%, while the annual FY2025 figure was $2.3 million, 7.7% down from the prior year.
  • Depreciation & Amortization (CF) reached $523000.0 in Q4 2025 per HRTX's latest filing, down from $615000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $794000.0 in Q4 2021 to a low of $523000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $680100.0, with a median of $711000.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): grew 19.0% in 2021, then fell 20.08% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $794000.0 in 2021, then dropped by 0.38% to $791000.0 in 2022, then dropped by 9.48% to $716000.0 in 2023, then decreased by 18.85% to $581000.0 in 2024, then fell by 9.98% to $523000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Depreciation & Amortization (CF) are $523000.0 (Q4 2025), $615000.0 (Q3 2025), and $611000.0 (Q2 2025).